WallStreetZenWallStreetZen

NASDAQ: RNAC
Cartesian Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their RNAC stock forecasts and price targets.

Forecast return on equity

Is RNAC forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.11%

Forecast return on assets

Is RNAC forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RNAC revenue forecast

What is RNAC's revenue in the next 1 years based on estimates from 2 analysts?
Avg 1 year Forecast
$61.6M+78.24%
RNAC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNAC revenue growth forecast

How is RNAC forecast to perform vs Biotechnology companies and vs the US market?
Company
24.09%
Industry
45.89%
Market
10.82%
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNAC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAC$0.69N/AN/A
CRVS$2.18$4.00+83.49%Strong Buy
TSBX$4.62N/AN/A
OTLK$0.41$2.60+539.16%Strong Buy
EYEN$2.37$10.00+321.94%Strong Buy

Cartesian Therapeutics Stock Forecast FAQ

What is RNAC's revenue growth forecast for 2024-2024?

(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 24.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.82%.

Cartesian Therapeutics's revenue in 2024 is $34,533,000.

In 2024, RNAC is forecast to generate $9,552,817,402 in revenue, with the lowest revenue forecast at $3,104,083,640 and the highest revenue forecast at $16,001,551,164.

If you're new to stock investing, here's how to buy Cartesian Therapeutics stock.

What is RNAC's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RNAC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RNAC's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RNAC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.